Peter S Grimison
Overview
Explore the profile of Peter S Grimison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou D, Connolly E, Mar J, Lazarakis S, Grimison P, Connor J, et al.
Cancer Treat Rev
. 2023 Dec;
122:102663.
PMID: 38039565
Background: In primary localised resectable retroperitoneal sarcoma (RPS), loco-regional and distant relapse occur frequently despite optimal surgical management. The role of chemotherapy in improving outcomes is unclear. Methods: A systematic...
2.
Connolly E, Grimison P, Horvath L, Robinson P, Reddel R
Front Oncol
. 2023 May;
13:1126736.
PMID: 37197427
Sarcoma is a rare and complex disease comprising over 80 malignant subtypes that is frequently characterized by poor prognosis. Challenges in clinical management include uncertainties in diagnosis and disease classification,...
3.
Bendell J, LoRusso P, Overman M, Noonan A, Kim D, Strickler J, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(7):2443-2458.
PMID: 37016126
Background: CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with...
4.
Strach M, Grimison P, Hong A, Boyle R, Stalley P, Karim R, et al.
Cancer Med
. 2022 May;
12(1):368-378.
PMID: 35603739
Background: Mesenchymal chondrosarcoma (MCS) is an ultra-rare sarcoma that follows a more aggressive course than conventional chondrosarcoma. This study evaluates prognostic factors, treatments (surgery, chemotherapy, and radiation), and outcomes in...
5.
Connolly E, Bhadri V, Wake J, Ingley K, Lewin J, Bae S, et al.
Cancer Med
. 2022 Feb;
11(8):1805-1816.
PMID: 35178869
Methods: A multi-centre retrospective cohort study of patients diagnosed between 2014-2019. Results: Eighteen patients were identified. The median age was 27 years (range 13-56), 10 patients were male (56%), 11...
6.
Olson T, Murray M, Rodriguez-Galindo C, Nicholson J, Billmire D, Krailo M, et al.
J Clin Oncol
. 2015 Aug;
33(27):3018-28.
PMID: 26304902
During the past 35 years, survival rates for children with extracranial malignant germ cell tumors (GCTs) have increased significantly. Success has been achieved primarily through the application of platinum-based chemotherapy...
7.
Costa D, Aaronson N, Fayers P, Grimison P, Janda M, Pallant J, et al.
Patient Relat Outcome Meas
. 2014 Nov;
5:119-29.
PMID: 25395875
Background: Multi attribute utility instruments (MAUIs) are preference-based measures that comprise a health state classification system (HSCS) and a scoring algorithm that assigns a utility value to each health state...
8.
Fox P, Chatfield M, Beith J, Allison S, Della-Fiorentina S, Fisher D, et al.
ANZ J Surg
. 2012 Sep;
83(7-8):533-8.
PMID: 22984845
Background: Delays in commencing adjuvant chemotherapy for early breast cancer beyond 12 weeks are associated with increased mortality. The aim of this study was to identify factors delaying chemotherapy in...
9.
Stockler M, Harvey V, Francis P, Byrne M, Ackland S, Fitzharris B, et al.
J Clin Oncol
. 2011 Oct;
29(34):4498-504.
PMID: 22025143
Purpose: We compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive regimens....
10.
Grimison P, Stockler M, Thomson D, Olver I, Harvey V, Gebski V, et al.
J Natl Cancer Inst
. 2010 Jul;
102(16):1253-62.
PMID: 20631341
Background: The Australian and New Zealand Germ Cell Trials Group conducted a multicenter randomized phase III trial in men with good-prognosis germ cell tumors of two standard chemotherapy regimens that...